In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Cardiovascular Pharmacotherapy in Women

Online training course by the ESC Working Group on Cardiovascular Pharmacotherapy

17/02/2022 14:00 18/02/2022 20:30 Europe/Paris Cardiovascular Pharmacotherapy in Women

Access event page

ESC Working Group on Cardiovascular Pharmacotherapy contact@escardio.org DD/MM/YYYY
Pharmacology and Pharmacotherapy
Online
event

Summary

The course will address unmet needs and knowledge gaps in the management of cardiovascular disease in women and aims at providing a balanced and practical view on the topic. Particular emphasis will be put on gender specific risk factors, dosing, evidence-based treatments and prevention of disease.



Registration

Registration fees

Category Price (excl. VAT)
Standard Fee 80€
Working Group Members Fee* 30€
Reduced Fee** 25€

 

* Individuals must be a member of the ESC WG CVP at the moment of registration in order to benefit from the member fee. Not yet a member ? Join now: membership is free.

** Applies to students, trainees, nurses: proof of status will be required (letter from University, etc)

Register now

You will be redirected to an external website managed by our technical partner, Barcelo Congresos. For any questions or queries, please do not hesitate to contact us: workinggroups@escardio.org

Join the ESC Working Group on Cardiovascular Pharmacotherapy

To learn more, benefit from savings and stay updated in the field, join the Working Group now.

Membership is free.

Who should attend

Reducing cardiovascular disease burden by pharmacotherapy represents a major challenge that requires specific knowledge and expertise. A multistep approach to the problem is needed to gain insight into the following key areas of knowledge.

Regarding defined patient groups in whom pharmacotherapy has specific requirements, women feature prominently. Marked knowledge gaps exist in relation to cardiovascular pharmacotherapy in women mainly associated to the fact that treatments are often extrapolated from those that have been shown to be mainly effective in men, dosing is often inappropriate as sparse data exist in the literature regarding gender differences in response to pharmacotherapy due to poor representation of women in clinical trials. Gender specific risk factors are often ignored or neglected.

Healthcare professionals responsible for the care of women with cardiovascular conditions, as well as trainees aiming to enter these fields, will benefit from this educational training course.

Learning objectives

Complementary to the All About Clinical Trials course, and the Pharmacotherapy in Older People Course, the Cardiovascular Pharmacotherapy in Women course aims to improve competency and confidence of participants in:

  • Bridging knowledge gaps regarding cardiovascular treatment and risk assessment of female patients
  • The assessment of both cardiovascular risk and the effect of pharmacotherapy in women
  • Identifying enablers and barriers in the management of female patients with cardiovascular conditions
  • The management of specific women issues related to cardiovascular pharmacotherapy

Scientific programme

Conference scientific committee

  • Prof. Juan Carlos Kaski, course director
  • Prof. Anne Gret Semb, course co-director

Format

The course will be delivered online, over two half days (from approx. 1PM-6PM each day).

The sessions will be made available on demand for one month after course, to registered delegates (although in order to claim CME credits, you will need to watch the sessions live).

Faculty

Learn directly from the world-renowned experts in the field !

Confirmed faculty include :

  • Juan Carlos Kaski, UK
  • Anne Grete Semb, NW
  • Alexander Niessner, AT
  • Heinz Drexel, AT
  • Sven Wassman, DE
  • Gianluigi Savarese, NW
  • Basil Lewis, IS
  • Juan Tamargo, SP
  • Elisabetta Cerbai, IT
  • Dobromir Dobrev, DE
  • Patrick Sulzgruber, AT
  • Stefan Agewall, NO
  • Iris Baumgartner, CH

CME accreditation

ESC submits its educational programmes (including online programmes) to the UEMS-EACCME for accreditation. The European Accreditation Council for Continuing Medical Education (EACCME) is an institution of the European Union of Medical Specialists (UEMS) responsible for the evaluation and accreditation of Medical Education Programmes.

Preliminary programme

All of the sessions include a 10-15min discussion time with the expert faculty.

Download the preliminary programme

SESSION 1. CARDIOVASCULAR RISK IN WOMEN

  • Conventional and gender specific risk factors in women
  • The importance of menopause in coronary disease progression- Clinical and epidemiological data
  • Assessing cardiovascular disease in women – Biases and unmet needs

SESSION 2: PHARMACOTHERAPY FOR CARDIOVASCULAR DISEASE IN PREGNANCY

  • CV pharmacotherapy – Which agents cannot be used and why?
  • Management of pre-eclampsia and eclampsia

SESSION 3. HYPERTENSION

  • Specific BP management issues in women – the ESC Guidelines
  • Sex disparities in response to anti-hypertensive medications: time for action

SESSION 4. HEART FAILURE – NEW INSIGHTS IN WOMEN

  • HFrEF and HFpEF
  • Takotsubo syndrome
  • Drug therapy in HF

SESSION 5: CARDIAC ARRHYTHMIA MANAGEMENT IN WOMEN

  • Cardiac arrhythmias in women – tips for diagnosis and management
  • Atrial fibrillation – stroke risk – DOACs – bleeding issues

SESSION 6. STABLE ISCHAEMIC HEART DISEASE IN WOMEN – DIAGNOSIS AND MANAGEMENT

  • Obstructive CAD – gender differences
  • INOCA – diagnosis and treatment
  • Case presentations and discussion

SESSION 7: ACUTE CORONARY SYNDROME – GENDER DIFFERENCES

  • Coronary dissection
  • ACS presentation and diagnosis – gender differences
  • Management of ACS: special considerations in women

SESSION 8. PRIMARY AND SECONDARY PREVENTION IN WOMEN - LIPID LOWERING AGENTS, ANTI-DIABETIC DRUGS – ANTIPLATELET AND ANTICOAGULATION

  • Management of dyslipidaemia
  • Diabetes, obesity, uric acid
  • Antiplatelet agents and DOACs in primary and secondary prevention

SESSION 9. EPIDEMIOLOGY – LESSONS FROM CLINICAL TRIALS AND REGISTRIES

  • Acute coronary syndromes – CAD ACS and MINOCA
  • Gender differences in cardiac care and outcome
  • Gender discrimination issues in cardiac diagnosis and care

SESSION 10. OTHER VASCULAR DISEASES 

  • Clinical outcomes in women after TAVR: results from the WIN-TAVI (Women's INternational Transcatheter Aortic Valve Implantation)
  • Peripheral artery disease treatments in women

SESSION 11. INFLAMMATION – AUTOIMMUNE DISEASES AND ISCHAEMIC HEART DISEASE

  • Cardiovascular disease and prevention in female patients with RA
  • SLE and antiphospholipid syndrome in women

Annual training programme of the ESC Working Group on Cardiovascular Pharmacotherapy

This course is part of an annual training programme designed to gain insight into the following key areas of knowledge:

  • The identification of new potentially effective pharmacological agents
  • The effective testing of new pharmacological compounds in the clinical setting
  • The complexities of regulatory approval
  • The safe and efficient implementation of cardiovascular pharmacotherapy in clinical practice
  • The specific needs of different patient groups i.e., the older individuals and women
  • Understanding the current unmet needs regarding pharmacotherapy and assessing and implementing evidence-based recommendations

Other courses include the All About Clinical Trials course and the Pharmacotherapy in Older People course.

Learn more